文献速递膀胱癌与上尿路尿路上皮癌

肿瘤位置可能预测膀胱癌根治性治疗后的不良病理和生存:一项全国队列研究

Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study.
PubMed 文献 · Eur Urol Oncol · 2018-09-14

基于美国国家癌症数据库(2010-2015年)的非转移性膀胱尿路上皮癌患者,接受根治性膀胱切除术(3464例)或放化疗(699例)。根治性膀胱切除术后,三角区肿瘤患者淋巴结阳性(31%)和晚期分期(59%)比例最高,前壁肿瘤最低(19%和50%)。三角区肿瘤与淋巴结阳性风险增加相关,膀胱颈肿瘤与淋巴结阳性相关,顶壁肿瘤与晚期分期相关;放化疗患者中三角区受累与更差总生存相关。

要点

  • 根治性膀胱切除术后,三角区肿瘤患者淋巴结阳性率为31%,前壁肿瘤为19%。
  • 三角区肿瘤与淋巴结阳性风险增加相关(OR 1.65,95%CI 1.12-2.43,p=0.012)。
  • 膀胱颈肿瘤与淋巴结阳性风险增加相关(OR 1.79,95%CI 1.11-2.90,p=0.018)。

核心结论

  • 三角区和膀胱颈肿瘤与淋巴结阳性风险增加相关,顶壁肿瘤与根治性膀胱切除术后更高肿瘤分期相关。
  • 三角区受累患者接受放化疗后总生存可能更差。

研究设计与样本

  • 全国队列研究,使用美国国家癌症数据库(2010-2015年)数据。
  • 纳入非转移性膀胱尿路上皮癌患者,接受根治性膀胱切除术(n=3464)或放化疗(n=699)。
  • 采用多变量逻辑回归评估肿瘤位置预测根治性膀胱切除术后不良病理(淋巴结转移[pN+]或晚期分期[pT3-4])的能力,采用Cox回归分析肿瘤位置对总生存的影响。

主要发现

  • 根治性膀胱切除术后,822例(24%)患者为pN+,1551例(55%)为pT3-4。
  • 三角区肿瘤不良病理比例最高(31% pN+和59% pT3-4),前壁肿瘤最低(19% pN+和50% pT3-4)。
  • 相对于前壁,三角区肿瘤与pN+风险增加相关(OR 1.65,95%CI 1.12-2.43,p=0.012),膀胱颈肿瘤与pN+风险增加相关(OR 1.79,95%CI 1.11-2.90,p=0.018),顶壁肿瘤与pT3-4风险增加相关(OR 1.56,95%CI 1.08-2.24,p=0.017)。
  • 接受放化疗的患者中,三角区受累与更差总生存相关(HR 1.58,95%CI 1.17-2.13,p=0.003)。

局限性

  • 存在未测量的变量。
  • 某些肿瘤位置的患者数量相对较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While urothelial carcinoma of the bladder is often considered a multifocal disease, the location of the dominant tumor may be prognostic. OBJECTIVE: To determine the association between intravesical tumor location and both adverse pathological outcomes as well as overall survival. DESIGN, SETTINGS, AND PARTICIPANTS: Patients in the National Cancer Database (2010-2015) with nonmetastatic urothelial carcinoma of the bladder who underwent primary treatment with radical cystectomy (RC; n=3464) or chemoradiotherapy (CRT; n=699). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regressions assessed the prognostic ability of tumor location to predict adverse pathology at RC (nodal metastases [pN+] or advanced stage [pT3-4]). Cox regressions were used to determine the effect of tumor location on overall survival in patients treated with RC or CRT. RESULTS AND LIMITATIONS: Following RC, 822 (24%) patients were pN+ and 1551 (55%) were pT3-4. Trigonal tumors were most likely to have adverse pathology (31% pN+ and 59% pT3-4), while anterior wall tumors were the least (19% pN+ and 50% pT3-4). Relative to the anterior wall, trigone (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.12-2.43, p=0.012) and bladder neck (OR 1.79, 95% CI 1.11-2.90, p=0.018) tumors were associated with increased odds of pN+ and dome (OR 1.56, 95% CI 1.08-2.24, p=0.017) with pT3-4. In those patients treated with primary CRT, trigone involvement was associated with worse survival (HR 1.58, 95% CI 1.17-2.13, p=0.003). Limitations included unmeasured variables and a relatively few number of patients with certain tumor locations. CONCLUSIONS: Trigone and bladder neck tumors are associated with increased odds of nodal involvement, and dome with a higher tumor stage at RC. Patients with trigone involvement may have worse overall survival following CRT. PATIENT SUMMARY: Location of the tumor within the bladder may be associated with worse cancer staging at the time of the surgery and worse survival following chemoradiotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Weiner AB, Desai AS, Meeks JJ, et al. Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. Eur Urol Oncol. 2018. PMID: 31200845. doi:10.1016/j.euo.2018.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。